Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 14;9(10):ofac476.
doi: 10.1093/ofid/ofac476. eCollection 2022 Oct.

PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals With HCV

Kristi C Hill  1   2 , Sarah M Kattakuzhy  3 , Rachel Silk  3 , Rahwa Eyasu  3 , Onyinyechi Ogbumbadiugha  3 , Emade Ebah  3 , Amelia A Cover  3 , Ashley Davis  3 , Britt Gayle  3 , David Sternberg  4 , Phyllis Bijole  4 , Junfeng Sun  5 , Henry Masur  5 , Shyam Kottilil  3 , Daniel Solomon  1 , Elana S Rosenthal  3
Affiliations

PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals With HCV

Kristi C Hill et al. Open Forum Infect Dis. .

Abstract

Background: Individuals with hepatitis C (HCV) represent a population that may benefit from pre-exposure prophylaxis (PrEP), given the overlapping risk factors and transmission networks of HCV and HIV. This analysis assesses the prevalence of PrEP indications among individuals with HCV monoinfection and PrEP awareness, interest, and access in this population.

Methods: GRAVITY was an observational study for the collection of epidemiologic data from individuals with HCV and/or HIV in Washington DC and Baltimore, with the present analysis limited to HCV-monoinfected patients. The prevalence of PrEP indications was determined using epidemiologic survey responses. Bivariate and multivariable analyses assessed for associations between PrEP indications and PrEP awareness, access, and interest.

Results: Among 314 HCV-monoinfected participants, 109 (35%) had an indication for PrEP. Forty-eight (44%) had a drug use indication alone, 40 (37%) had a sexual indication alone, and 21 (19%) had both drug use and sexual indications. Eighty-five (27%) participants had heard of PrEP, 32 (10%) had been offered PrEP by a provider, 114 (38%) were interested or maybe interested in PrEP, and 6 (2%) were currently taking PrEP. On bivariate analysis, PrEP awareness was significantly associated with study site (P < .0001), race (P = .0003), age (P < .0001), and sexual PrEP indication (P = .04). However, only study site remained significant (P = .0002) on regression analysis.

Conclusions: Though indications for PrEP were prevalent among individuals with HCV in this cohort, most patients were unaware of PrEP, had never been offered PrEP, and were not using PrEP. These data support the need for improved PrEP implementation among people with HCV.

Keywords: HCV; HIV; HIV prevention; PWID; PrEP; hepatitis C; people who inject drugs; pre-exposure prophylaxis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PrEP eligibility and HIV risk perception. Abbreviation: PrEP, pre-exposure prophylaxis.
See this image and copyright information in PMC

References

    1. Chou R, Evans C, Hoverman A, et al. . Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019; 321:2214–30. - PubMed
    1. Landovitz RJ, Donnell D, Clement ME, et al. . Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021; 385:595–608. - PMC - PubMed
    1. Harris NS, Johnson AS, Huang YA, et al. . Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis United States, 2013–2018. MMWR Morb Mortal Wkly Rep 2019; 68:1117–23. - PMC - PubMed
    1. Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019; 22:e25348. - PMC - PubMed
    1. Centers for Disease Control and Prevention . HIV surveillance report.2020. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 31 May 2022.